AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21883424 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gel with triester glycerol oxide (TGO)
Number of subjects: 50
Study 21883424 — intervention group
Group type: COMPARATOR
Intervention: Topical gel without triester glycerol oxide (placebo)
Number of subjects: 50
Study 20085628 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (50:40:10 mixture of medium-chain fatty acids, soybean oil, and fish oil)
Number of subjects: 25
Study 20085628 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 25
Study 20085628 — intervention group
Group type: COMPARATOR
Intervention: Control (50:50 mixture of medium-chain fatty acids and soybean oil)
Number of subjects: 25
Study 17889972 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 25
Study 17889972 — intervention group
Group type: EXPERIMENTAL
Intervention: Unanticipated landings
Number of subjects: 25
Study 17889972 — intervention group
Group type: COMPARATOR
Intervention: Anticipated landings
Number of subjects: 25
Study 15699240 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg daily for 14 days)
Number of subjects: 56
Study 15699240 — intervention group
Group type: COMPARATOR
Intervention: Control (multivitamins plus calcium)
Number of subjects: 56
Study 12028744 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 136
Study 12028744 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 136
Study 10228607 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizandra chinensis and Bryonia alba extracts
Number of subjects: 0
Study 10228607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10228607 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptogens (Schizandra chinensis and Bryonia alba)
Number of subjects: 0
Study 9057338 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic magnetic resonance imaging (MRI) with 10 micrograms intrapenile prostaglandin E1
Number of subjects: 25
Study 9057338 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ultrasonography (US)
Number of subjects: 25
Study 9057338 — intervention group
Group type: EXPERIMENTAL
Intervention: Spin echo (SE) sequences
Number of subjects: 25
Study 1853145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocloprost (100 micrograms/dose)
Number of subjects: 10
Study 1853145 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 10
Study 1853145 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (2.5 g)
Number of subjects: 10
Study 6348577 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary volume expansion, vasodilators, and centrally acting drugs
Number of subjects: 30
Study 6348577 — intervention group
Group type: COMPARATOR
Intervention: Classical treatment for hypertension with a diuretic
Number of subjects: 30
Study 31873786 — intervention group
Group type: EXPERIMENTAL
Intervention: prn-IVB
Number of subjects: 100
Study 31873786 — intervention group
Group type: EXPERIMENTAL
Intervention: prn-IVT
Number of subjects: 100
Study 30897031 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic CHO (HCHO; 6% CHO provided as 2 ml/kg/15 min; FiO2 = 16.3%)
Number of subjects: 10
Study 30897031 — intervention group
Group type: COMPARATOR
Intervention: Hypoxic placebo (HPLA; FiO2 = 16.3%)
Number of subjects: 10
Study 30897031 — intervention group
Group type: COMPARATOR
Intervention: Normoxic placebo (NPLA; FiO2 = 20.9%)
Number of subjects: 10
Study 28562792 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing appointments (three appointments alternated bimonthly with two phone calls over five months)
Number of subjects: 134
Study 28562792 — intervention group
Group type: COMPARATOR
Intervention: Usual care offered by the Health Unit
Number of subjects: 134
Study 26376281 — intervention group
Group type: EXPERIMENTAL
Intervention: MUAC < 115 mm
Number of subjects: 0
Study 26376281 — intervention group
Group type: COMPARATOR
Intervention: Current admission criteria (WHZ < -3 and/or MUAC < 115 mm)
Number of subjects: 0
Study 23676888 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 141
Study 23676888 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 141
Study 21472441 — intervention group
Group type: EXPERIMENTAL
Intervention: Target guidance
Number of subjects: 0
Study 21472441 — intervention group
Group type: EXPERIMENTAL
Intervention: Path guidance
Number of subjects: 0
Study 21472441 — intervention group
Group type: COMPARATOR
Intervention: No-guidance
Number of subjects: 0
Study 21472441 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive path guidance
Number of subjects: 0
Study 21472441 — intervention group
Group type: COMPARATOR
Intervention: No-guidance (in second experiment)
Number of subjects: 0
Study 20355225 — intervention group
Group type: COMPARATOR
Intervention: Measurement of insulin-like growth factor-I (IGF-I) and type III pro-collagen (P-III-P) as markers of GH action
Number of subjects: 0
Study 20355225 — intervention group
Group type: COMPARATOR
Intervention: Immunoassays recognizing different isoforms of pituitary GH
Number of subjects: 0
Study 17088488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV) 200 mg QD
Number of subjects: 36
Study 17088488 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir (RTV) 100 mg QD
Number of subjects: 36
Study 14741072 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT‐A as BOTOX)
Number of subjects: 167
Study 11706485 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical revision
Number of subjects: 94
Study 11706485 — intervention group
Group type: COMPARATOR
Intervention: Expectation (observation)
Number of subjects: 94
Study 9027267 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg twice daily)
Number of subjects: 146
Study 9027267 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 146
Study 8068051 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable protein diet
Number of subjects: 8
Study 8068051 — intervention group
Group type: COMPARATOR
Intervention: Animal protein diet
Number of subjects: 8
Study 3318377 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose carbonyl iron 600 mg three times per day
Number of subjects: 36
Study 3318377 — intervention group
Group type: COMPARATOR
Intervention: Standard ferrous sulfate 60 mg three times per day
Number of subjects: 36
Study 29967325 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath Concurrence 6 (BC6)
Number of subjects: 0
Study 29967325 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Ectopia (PE)
Number of subjects: 0
Study 29967325 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BC6 and Deceleration Capacity (DC)
Number of subjects: 0
Study 29967325 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PE and Deceleration Capacity (DC)
Number of subjects: 0
Study 27079740 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizoribine and steroid
Number of subjects: 55
Study 27079740 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and steroid
Number of subjects: 55
Study 25840742 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (dopamine D2-receptor antagonist)
Number of subjects: 0
Study 25840742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23485622 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 6486
Study 23485622 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6486
Study 21276284 — intervention group
Group type: EXPERIMENTAL
Intervention: Rplus
Number of subjects: 13
Study 21276284 — intervention group
Group type: EXPERIMENTAL
Intervention: Lplus
Number of subjects: 13
Study 21276284 — intervention group
Group type: COMPARATOR
Intervention: Provox Normal
Number of subjects: 13
Study 21276284 — intervention group
Group type: EXPERIMENTAL
Intervention: Rplus and Lplus
Number of subjects: 13
Study 21276284 — intervention group
Group type: COMPARATOR
Intervention: Stomvent
Number of subjects: 13
Study 19036851 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (300 microg of selenium a day as high‐selenium yeast for 48 weeks)
Number of subjects: 0
Study 19036851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 17014912 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy‐led lifestyle treatment
Number of subjects: 67
Study 17014912 — intervention group
Group type: COMPARATOR
Intervention: Routine GP care
Number of subjects: 67
Study 15482080 — intervention group
Group type: EXPERIMENTAL
Intervention: Day treatment plus abstinent-contingent housing and work (DT+)
Number of subjects: 141
Study 15482080 — intervention group
Group type: COMPARATOR
Intervention: Day treatment only (DT)
Number of subjects: 141
Study 11534312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 40
Study 11534312 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask (LMA)
Number of subjects: 40
Study 9625308 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg three times daily)
Number of subjects: 36
Study 9625308 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (3 MU three times per week)
Number of subjects: 36
Study 7574219 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 325 mg/d
Number of subjects: 372
Study 7574219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 2168814 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong and antihypertensive drugs at low dosage
Number of subjects: 61
Study 2168814 — intervention group
Group type: COMPARATOR
Intervention: WM group (antihypertensive drugs alone)
Number of subjects: 61
Study 528285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural BCG
Number of subjects: 22
Study 528285 — intervention group
Group type: COMPARATOR
Intervention: Intrapleural saline
Number of subjects: 22
Study 30156030 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 levels in patients with acute influenza
Number of subjects: 50
Study 30156030 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CoQ10 levels (<0.5 μg/mL) in patients with acute influenza
Number of subjects: 50
Study 30156030 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of CoQ10 levels with inflammatory biomarkers in influenza patients
Number of subjects: 50
Study 28359749 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention plus omega 3 polyunsaturated fatty acids (800 mg DHA and 225 mg EPA daily)
Number of subjects: 1680
Study 28359749 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention plus placebo
Number of subjects: 1680
Study 28359749 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega 3 polyunsaturated fatty acids alone
Number of subjects: 1680
Study 28359749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1680
Study 25283851 — intervention group
Group type: EXPERIMENTAL
Intervention: The Original Sound (TOS)
Number of subjects: 34
Study 25283851 — intervention group
Group type: COMPARATOR
Intervention: Environmental noise
Number of subjects: 34
Study 25125097 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (Deep NMB)
Number of subjects: 57
Study 25125097 — intervention group
Group type: COMPARATOR
Intervention: No neuromuscular blockade (No NMB)
Number of subjects: 57
Study 25125097 — intervention group
Group type: COMPARATOR
Intervention: No NMB
Number of subjects: 57
Study 25125097 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep NMB
Number of subjects: 57
Study 23565930 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine irrigation (30 mL of 2% prilocaine)
Number of subjects: 50
Study 23565930 — intervention group
Group type: COMPARATOR
Intervention: Control group (prilocaine-free irrigation solution)
Number of subjects: 50
Study 21718536 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forests classifiers using 160-320 SNPs
Number of subjects: 417
Study 21718536 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forests classifiers using 10 SNPs
Number of subjects: 417
Study 21718536 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical traits alone
Number of subjects: 417
Study 18765042 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality training device
Number of subjects: 16
Study 18765042 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-enhanced training device
Number of subjects: 16
Study 17169156 — intervention group
Group type: EXPERIMENTAL
Intervention: Men aged > or = 70 years at baseline
Number of subjects: 2447
Study 17169156 — intervention group
Group type: EXPERIMENTAL
Intervention: Men who had suffered a stroke
Number of subjects: 2447
Study 17169156 — intervention group
Group type: COMPARATOR
Intervention: Men without stroke
Number of subjects: 2447
Study 14620170 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 56
Study 14620170 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 56
Study 10911005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery
Number of subjects: 48
Study 10911005 — intervention group
Group type: COMPARATOR
Intervention: Continued medical treatment
Number of subjects: 48
Study 9022529 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic + Fish Oil
Number of subjects: 50
Study 9022529 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic
Number of subjects: 50
Study 9022529 — intervention group
Group type: COMPARATOR
Intervention: Fish Oil
Number of subjects: 50
Study 7931883 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic phototherapy
Number of subjects: 270
Study 7931883 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy (daylight fluorescent lamps)
Number of subjects: 270
Study 7931883 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination phototherapy
Number of subjects: 270
Study 3154682 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol
Number of subjects: 18
Study 3154682 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 18
Study 30130712 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcosine (2 g)
Number of subjects: 60
Study 30130712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27770784 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanically informed training program
Number of subjects: 30
Study 27770784 — intervention group
Group type: COMPARATOR
Intervention: Generic training program
Number of subjects: 30
Study 25743428 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 96
Study 25743428 — intervention group
Group type: COMPARATOR
Intervention: Pre-ART
Number of subjects: 96
Study 23915796 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics (mixture of galacto-oligosaccharide and polydextrose 1:1)
Number of subjects: 94
Study 23915796 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GG)
Number of subjects: 94
Study 23915796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 23915796 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 94
Study 21913862 — intervention group
Group type: EXPERIMENTAL
Intervention: Home bleaching (Opalescence 35% Carbamide Peroxide)
Number of subjects: 30
Study 21913862 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically activated office bleaching (Opalescence Xtra Boost 38% Hydrogen Peroxide)
Number of subjects: 30
Study 21913862 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-activated office bleaching (Opalescence Xtra 35% Hydrogen Peroxide)
Number of subjects: 30
Study 21913862 — intervention group
Group type: COMPARATOR
Intervention: Home and chemically activated bleaching systems
Number of subjects: 30
Study 18984493 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based program for obese children and adolescents consisting of modules for physical activity, nutritional education, and coping strategies performed twice each week for 1 year with parental participation and medical supervision.
Number of subjects: 73
Study 18984493 — intervention group
Group type: COMPARATOR
Intervention: Written therapeutic advice during a visit at 0 and 6 months in the outpatient clinic.
Number of subjects: 73
Study 16706813 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient drink
Number of subjects: 30
Study 16706813 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 30
Study 16706813 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient drink and Water
Number of subjects: 30
Study 12582838 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA(A) agonist lorazepam
Number of subjects: 0
Study 12582838 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive training (motor learning task)
Number of subjects: 0
Study 11078104 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice schedule
Number of subjects: 0
Study 11078104 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice schedule
Number of subjects: 0
Study 9206051 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen therapy (20mg daily for 2 to 5 years)
Number of subjects: 874
Study 9206051 — intervention group
Group type: COMPARATOR
Intervention: No tamoxifen therapy (control group)
Number of subjects: 874
Study 8154420 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular aneurysm patients
Number of subjects: 2494
Study 8154420 — intervention group
Group type: COMPARATOR
Intervention: No wall motion abnormalities
Number of subjects: 2494
Study 2835055 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 2,500 U s.c. once daily
Number of subjects: 231
Study 2835055 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) 5,000 U s.c. twice daily with dihydroergotamine (DHE) 0.5 mg s.c.
Number of subjects: 231
Study 31424354 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min Stroop task
Number of subjects: 20
Study 31424354 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min Stroop task
Number of subjects: 20
Study 31424354 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 30064032 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil
Number of subjects: 16
Study 30064032 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil plus Sn solution
Number of subjects: 16
Study 30064032 — intervention group
Group type: COMPARATOR
Intervention: Sn solution (positive control)
Number of subjects: 16
Study 30064032 — intervention group
Group type: COMPARATOR
Intervention: Deionized water (negative control)
Number of subjects: 16
Study 28283026 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Intrauterine System (LNG-IUS)
Number of subjects: 77
Study 28283026 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate injection (DMPA)
Number of subjects: 77
Study 28283026 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptive pill (COCP)
Number of subjects: 77
Study 28283026 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 77
Study 25528326 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-related colorectal cancer prevention beliefs
Number of subjects: 169
Study 23735957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular application of recombinant tissue‐type plasminogen activator and lateral rotational therapy (experimental)
Number of subjects: 60
Study 23735957 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 60
Study 20464617 — intervention group
Group type: COMPARATOR
Intervention: GONB and TPIs using lidocaine 2% and bupivacaine 0.5% + saline (group A)
Number of subjects: 37
Study 20464617 — intervention group
Group type: EXPERIMENTAL
Intervention: GONB and TPIs using lidocaine 2% and bupivacaine 0.5% + triamcinolone 40 mg (group B)
Number of subjects: 37
Study 18467729 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/fluorouracil/vincristine (CFV)
Number of subjects: 173
Study 18467729 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/doxorubicin (CD)
Number of subjects: 173
Study 16371294 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestorone/ethinylestradiol vaginal ring inserted during the follicular phase for 7 consecutive days
Number of subjects: 48
Study 14609894 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 1 g of EMLA 60 to 90 minutes before lumbar puncture
Number of subjects: 60
Study 14609894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10907384 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith repositioning procedure (CRP)
Number of subjects: 50
Study 10907384 — intervention group
Group type: COMPARATOR
Intervention: Sham maneuver
Number of subjects: 50
Study 8677067 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (5 mg every 12 hours for a total of four doses)
Number of subjects: 124
Study 8677067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 124
Study 8677067 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (in singleton analysis)
Number of subjects: 124
Study 8677067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in singleton analysis)
Number of subjects: 124
Study 1464896 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg single dose)
Number of subjects: 20
Study 1464896 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (2 x 25 mg for two weeks)
Number of subjects: 20
Study 1464896 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 20
Study 1464896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6206035 — intervention group
Group type: EXPERIMENTAL
Intervention: cis‐platinum plus bleomycin
Number of subjects: 28
Study 6206035 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate plus vindesine
Number of subjects: 28
Study 6206035 — intervention group
Group type: EXPERIMENTAL
Intervention: surgery
Number of subjects: 28
Study 30677137 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimating equations (GEE)
Number of subjects: 2000
Study 30677137 — intervention group
Group type: COMPARATOR
Intervention: Conventional statistical tests (t-tests and ANOVAs)
Number of subjects: 2000
Study 27892822 — intervention group
Group type: EXPERIMENTAL
Intervention: EG2 (‐) - text focusing on negative changes
Number of subjects: 241